Core Viewpoint - The establishment of a 1 billion yuan investment fund by companies under China Resources, in collaboration with Shanghai Fosun Pharmaceutical and Chengdu state-owned enterprises, aims to focus on the pharmaceutical and health sectors, particularly in innovative drug development and strategic emerging industries [2][4]. Group 1: Fund Structure and Partners - The fund, named China Resources Pharmaceutical (Chengdu) Innovation Investment Fund, has a total capital of 100 million yuan, with various partners contributing different amounts [3]. - The general partner (GP) is China Resources Pharmaceutical (Chengdu) Enterprise Management Partnership (Limited Partnership), while limited partners (LPs) include several pharmaceutical companies and investment funds [2][3]. - The fund's lifespan is set for 7 years, with a 3-year investment period and a 4-year exit period, extendable by 1 year upon partner approval [3]. Group 2: Investment Focus - The fund will concentrate on the pharmaceutical health sector and strategic emerging industries, targeting areas such as chemical innovative drugs, biological drugs (including vaccines), high-end medical devices, and traditional Chinese medicine [4]. - The involvement of the Chengdu Bio-City Jingchuang Equity Investment Fund indicates a strong potential for project implementation within the Chengdu Tianfu International Bio-City [4]. Group 3: Historical Context - An earlier fund, the China Resources Pharmaceutical (Shantou) Industry Investment Fund, was established 8 years ago but did not perform as expected, failing to reach its initial target of 2.5 billion yuan [4][6]. - The Shantou fund entered a liquidation phase in December 2024, having not achieved the anticipated scale, which affected the contributions of its partners [5][6].

相信集团可充分利用基金专业投资团队的资源，通过基金有效控制并购及创新项目的风险，确保目标公 司的质量，储备优质战略项目资源，并加速集团的战略并购，从而实现其在医药行业的战略目标，提升 集团中长期的可持续发展能力。 格隆汇7月17日丨华润医药(03320.HK)公告，华润医药（成都）企业管理合伙企业（有限合伙）（作为 普通合伙人）、华润医药投资有限公司（公司的全资附属公司）、华润博雅生物制药集团股份有限公 司、东阿阿胶股份有限公司（公司的非全资附属公司）、华润双鹤药业股份有限公司（公司的非全资附 属公司）、江中药业股份有限公司（公司的非全资附属公司）、成都润药产业投资合伙企业（有限合 伙）（基金投资团队持有的雇员持股平台，为独立第三方），以及五名其他独立第三方（作为有限合伙 人）拟就成立合资基金（暂时名为华润医药（成都）创新投资基金合伙企业（有限合伙））订立有限合 伙协议，拟议规模为人民币10亿元，总年期为七年。集团的拟议资本承担总额将约为人民币245百万 元，占基金资本承担总额约24.5%。 预期基金将主要从事股权投资、创业资本及投资管理活动，主要投资医药及健康产业以及战略性新兴领 域。考虑到成都政府的产业政 ...